Delving into the Latest Updates on AltaRex Corp. with Synapse

概览

疾病领域	数量

内分泌与代谢疾病	1
肿瘤	1

排名前五的药物类型	数量

单克隆抗体	1

排名前五的靶点	数量

MUC1(黏蛋白-1)	1

关联

1

项与 AltaRex Corp. 相关的药物

Anti-MUC1 monoclonal antibody(AltaRex Corp.)

靶点

MUC1

作用机制

MUC1抑制剂

在研机构

HYULIM A-TECH Co., Ltd. [+3]

原研机构

AltaRex Corp.

在研适应症

胰腺癌

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

2

项与 AltaRex Corp. 相关的临床试验

NCT00004064 / Unknown status临床2期

A Randomized, Double-Blind, Placebo-Controlled, Phase IIB Study of the Safety and Efficacy of OVAREX MabB43.13 in Ovarian Cancer Patients With an Elevated Serum CA 125 But Without Other Evidence of Disease

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
PURPOSE: Randomized phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have ovarian, fallopian tube, or peritoneal cancer.

开始日期1998-11-01

申办/合作机构

AltaRex Corp.

NCT00003634 / Unknown status临床2期

A Double-Blind Placebo Controlled Trial of Intravenous OvaRex MAb-B43.13 as Post Chemotherapy Consolidation for Ovarian Tubal and Peritoneal Carcinoma

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether giving monoclonal antibody therapy is more effective than a placebo in treating patients with ovarian epithelial, fallopian tube, or peritoneal cancer who have responded to surgery and chemotherapy.
PURPOSE: Randomized phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients with residual disease from stage III or stage IV ovarian epithelial, fallopian tube, or peritoneal cancer following surgery and chemotherapy.

开始日期1998-04-01

申办/合作机构

AltaRex Corp.

100 项与 AltaRex Corp. 相关的临床结果

登录后查看更多信息

0 项与 AltaRex Corp. 相关的专利（医药）

登录后查看更多信息

4

项与 AltaRex Corp. 相关的文献（医药）

2004-12-01·Annals of Oncology1区 · 医学

Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity

1区 · 医学

Article

作者: C. F. Nicodemus ; P. Monroe ; S Gail Eckhardt ; B. C. Schultes ; E. K. Rowinsky ; T. L. Whiteside ; L. A. Hammond ; A. W. Tolcher ; J. M. Cermak ; S. Y. Rha ; J. S. de Bono ; J. Stephenson

BACKGROUNDBrevaRex mAb-AR20.5 is a murine anti-MUC1 monoclonal antibody generated to induce MUC1 antigen-specific immune responses through the formation of immune complexes with circulating MUC1 and/or MUC1-expressing tumor cells that may target these immune complexes (IC) to receptors on dendritic cells (DCs).PATIENTS AND METHODSA phase I study focusing on safety and immunology evaluated 1, 2 and 4-mg doses. Seventeen patients with MUC1-positive cancers received intravenous infusions of the antibody over 30 min on weeks 1, 3, 5, 9, 13 and 17 of treatment.RESULTSmAb-AR20.5 was well-tolerated, not associated with dose-limiting toxicity, and did not induce hypersensitivity reactions. Overall, five of 15 evaluable patients developed human anti-mouse antibodies (HAMA), five developed anti-idiotypic antibodies (Ab2) and seven developed anti-MUC1 antibodies. Immune responses were most prominent in the 2-mg dose cohort for all parameters tested, and treatment-emergent MUC1-specific T-cell responses were detected in five of 10 evaluable patients treated with mAb-AR20.5.CONCLUSIONSThe injection of a murine antibody to MUC1 induces MUC1-specific immune responses in advanced cancer patients. Anti-MUC1 antibody increases correlated with decrease or stabilization of CA15.3 levels (P=0.03). The 2-mg dose of mAb-AR20.5 showed strongest biological activity, and will be evaluated in future efficacy trials.

2004-07-15·Journal of Clinical Oncology

Relationship of time to relapse (TTR) and survival post relapse (SPR): Exploration of risk factors from the first annual follow-up data set of randomized pbo-controlled study of oregovomab (OV) as a consolidation therapy of patients with advanced ovarian cancer (OC)

作者: Berek, J. S. ; Schultes, B. ; Balser, J. ; Nicodemus, C. F. ; Taylor, P.

2001-06-01·Cancer Biotherapy and Radiopharmaceuticals4区 · 医学

Induction of CA125-Specific B and T Cell Responses in Patients Injected with MAb-B43.13—Evidence for Antibody-Mediated Antigen-Processing and Presentation of CA125 in Vivo

4区 · 医学

Article

作者: Noujaim, Antoine A. ; Schultes, Birgit C. ; Madiyalakan, Ragupathy ; Baum, Richard P.

The murine monoclonal anti-CA125 antibody MAb-B43.13 has previously been administered as an immunoscintigraphic agent in order to monitor recurrence of ovarian cancer in patients, and a long-term follow-up demonstrated a survival benefit for these patients. The clinical benefit was initially attributed to the activation of the idiotypic network. The objective of this study was to investigate the role of CA125-MAb-B43.13 immune complex formation on the induction of CA125-specific immune responses. Analysis of patient serum samples from pharmacokinetic studies demonstrated that the antibody forms immune complexes with CA125 in circulation within 30 minutes of injection. Induction of humoral and cellular anti-CA125 responses correlated with the amount of circulating CA125 antigen present at time of antibody injection. Subsequent to the injection of MAb-B43.13, the patients generated anti-CA125 antibodies that were directed against various epitopes on the antigen and were not restricted to the specific epitope recognized by MAb-B43.13. The generation of CA125-specific B and T cell responses after MAb-B43.13 injection correlated with improved survival. The influence of circulating CA125 for the induction of CA125-specific immune responses and the multi-epitopic nature of the human anti-CA125 antibodies suggest that the majority of these antibodies were not induced via the idiotypic network but by the autologous antigen itself. Since antibody and T cell responses to CA125 were not present before injection of MAb-B43.13, it is hypothesized that complex formation of MAb-B43.13 with circulating antigen triggers the induction of CA125-specific immune responses.

100 项与 AltaRex Corp. 相关的药物交易

登录后查看更多信息

100 项与 AltaRex Corp. 相关的转化医学

登录后查看更多信息